Sbir phase i award

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201100055C
Awardee
Awarding agency
Obligated
$199,938

Award facts

Contract value 100% obligated
$199,938.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
334510 Electromedical and Electrotherapeutic Apparatus Manufacturing
PSC
AJ91 R&D- General Science/Technology: Other (Basic Research)
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 251 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Dallas, TX 75201, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action 1 · The purpose of this contract is to define in vivo effectiveness of a melanoma-targeted nanoparticle for systemic therapeutic delivery. $149,938
Original award $50,000

Quick answers

Who was awarded contract HHSN261201100055C?

HHSN261201100055C was awarded to Gradalis, Inc. by National Cancer Institute (National Institutes of Health) on September 27, 2011.

How much is contract HHSN261201100055C worth?

The government has obligated $199,938 on HHSN261201100055C.

Was contract HHSN261201100055C competed?

The extent of competition for HHSN261201100055C was full and open competition after exclusion of sources. The government received 251 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award